Key Highlights
- Krish Patel, MD, appointed as Director of Lymphoma Research at Sarah Cannon Research Institute (SCRI).
- Dr. Patel to enhance lymphoma clinical trial portfolio at SCRI’s 250+ locations.
- Background includes roles at Swedish Cancer Institute and significant research publications in leading medical journals.
- Brings expertise in lymphoma, CLL, and cellular therapy.
Source: Business Wire
Notable Quote
- “We are pleased to welcome Dr. Patel as we continue our mission to provide cutting-edge clinical research in the community. Dr. Patel’s role will be pivotal in providing scientific leadership and oversight for our robust menu of lymphoma clinical trials, addressing a critical need with nearly 90,000 new U.S. cases of lymphoma estimated in 2023.” — David Spigel, Chief Scientific Officer at SCRI
SoHC's Take
The appointment of Dr. Krish Patel to Sarah Cannon Research Institute as Director of Lymphoma Research is a strategic enhancement to SCRI’s leadership in oncology clinical trials, specifically addressing the pressing need for innovative lymphoma treatments. With Dr. Patel’s extensive research background, including his leadership roles at Swedish Cancer Institute and expertise in cellular therapy, SCRI is positioned to expand its impact on lymphoma research. His appointment signifies a commitment to advancing research for one of the most common cancers in the U.S., providing hope and potential breakthroughs for the thousands affected by lymphoma annually.
